PanTheryx and Dr. Reddy’s Announce an Agreement to Market PanTheryx’s Proprietary Nutritional Intervention for Pediatric Infectious Diarrhea

Inc., a global medical nutrition company based in Boulder, Colorado, and Dr.
Reddy’s Laboratories Ltd.
(NYSE: RDY), a leading global
pharmaceutical company, announced today a multi-country supply and
licensing agreement. The agreement grants Dr. Reddy’s the exclusive
right to market and distribute PanTheryx’s breakthrough nutritional
intervention, DiaResQ®,
for infectious diarrhea in India and Nepal and in process for Russia,
Myanmar, Vietnam, Ukraine, Sri Lanka, Kazakhstan, Belarus, Jamaica, and
select LATAM markets. Dr. Reddy’s will market the product in India and
Nepal under the “Reliqua™” brand.

DiaResQ® helps promote intestinal repair and boost natural immune
defenses, resulting in the restoration of normal digestive function. The
product was recently recognized in Reimagining
Global Health
as one of the 30 leading healthcare
innovations with great promise to transform global health by 2030.

“The opportunity to work with Dr. Reddy’s to broadly introduce DiaResQ®
represents a significant milestone for our company,” said Mark A.
Braman, President and CEO of PanTheryx. “Dr. Reddy’s is the recognized
leader in the gastrointestinal market, and this agreement covers some of
the largest and most promising markets throughout the world for
PanTheryx and its products. This partnership further validates
DiaResQ’s® potential to improve the well-being and quality of life of
millions of children and their families globally.”

Dr. Reddy’s Co-chairman and CEO, GV Prasad stated, “This innovative
product will address a significant unmet need in the area of diarrhea.
By adding Reliqua to our existing portfolio of gastrointestinal brands,
Dr. Reddy’s can provide an important new tool for healthcare
practitioners across the many markets we serve. Our agreement with
PanTheryx is another step towards ensuring good health can be delivered
to those who need it.”

Infectious diarrhea is a major world health challenge. Globally,
approximately 1.7 billion cases occur annually in children under five.
Almost 760,000 of these children under five die every year as a result
of this condition. Pediatric infectious diarrhea kills nearly as many
children as HIV/AIDS, malaria and measles combined. (Source: World
Health Organization

About PanTheryx:

Founded in 2007, PanTheryx is a global medical nutrition company based
in Boulder, Colorado USA, and is dedicated to improving global health
and quality of life through innovative life science. Utilizing its
broad-based proprietary technology platform, PanTheryx is focused on the
research, development and commercialization of medical nutrition
products targeting the gastrointestinal microbiome. The company’s lead
product, DiaResQ®, addresses infectious diarrhea, a leading cause of
death worldwide among children under the age of five. For more
information, log on to:

About Dr. Reddy’s

Dr. Reddy’s Laboratories Ltd. is an integrated pharmaceutical company,
committed to accelerating access to affordable and innovative medicines,
because it believes Good Health Can’t Wait. Through its three businesses
– Pharmaceutical Services & Active Ingredients, Global Generics and
Proprietary Products – the company offers a portfolio of products and
services that include active pharmaceutical ingredients (APIs), custom
pharmaceutical services, generics, biosimilars and differentiated
formulations. With operations in 26 countries across the globe, the
major therapeutic areas of Dr. Reddy’s are gastro-intestinal,
cardiovascular, diabetology, oncology, pain management and
anti-infectives. For more information, log on to:


PanTheryx, Inc.
Rodney D Bell, 303-807-3397
Fletcher, 720-350-3144
Reddy’s Laboratories Ltd.
8-2-337, Road No. 3, Banjara Hills
500 034
Calvin Printer, +91.40.4900 2121